Harold Springs, MD
Endocrinology, Diabetes & Metabolism · Charlotte, NCNPI 1184808305
Payments from drug & device makers
Across 98 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$313
- Amgen$272
- Lilly USA, LLC$146
- Sanofi-aventis U.S. LLC$95
- AbbVie$83
- Mannkind Corporation$82
- plus $857 from 28 others
What the payments were for
- Food & beverage$1,82499%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $313 |
| Amgen(2 entities) | 14 | $272 |
| Lilly USA, LLC | 8 | $146 |
| Sanofi-aventis U.S. LLC | 4 | $95 |
| AbbVie | 5 | $83 |
| Mannkind Corporation | 4 | $82 |
| Boehringer Ingelheim | 4 | $75 |
| Abbott | 3 | $71 |
| Amneal Pharmaceuticals LLC | 3 | $61 |
| AstraZeneca(2 entities) | 3 | $55 |
| Radius Health, Inc. | 2 | $50 |
| Ascensia Diabetes Care US Inc. | 2 | $49 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| Cequr Corporation | 2 | $42 |
| Ascendis Pharma Endocrinology Inc | 2 | $40 |
| Bayer | 2 | $39 |
| Dexcom, Inc. | 2 | $37 |
| Shire North American Group Inc | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $25 |
| Novartis | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Lifescan, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Intuity Medical Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Companion Medical, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,849 in reported general payments places this provider in the 50th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 375 | $514,113 |
| MounjaroTirzepatide | 192 | $243,507 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $125,329 |
| Tresiba Flextouch U-200Insulin Degludec | 71 | $125,161 |
| Tresiba Flextouch U-100Insulin Degludec | 158 | $122,664 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 79 | $106,881 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $98,646 |
| TrulicityDulaglutide | 61 | $97,286 |
| JardianceEmpagliflozin | 40 | $65,642 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $41,551 |
| RybelsusSemaglutide | 28 | $40,530 |
| Novolog FlexpenInsulin Aspart | 103 | $35,014 |
| FarxigaDapagliflozin Propanediol | 30 | $31,352 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $26,773 |
| JanuviaSitagliptin Phosphate | 20 | $24,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $313 | $561,438415 claims |
| Lilly USA, LLCMounjaro, Trulicity | $146 | $340,792253 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $75 | $184,856135 claims |
| AstraZenecaFarxiga | $55 | $31,35230 claims |
| AbbVieSynthroid | $83 | $7,18467 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $61 | $3,359354 claims |
| Sanofi-aventis U.S. LLCLantus | $95 | $2,15111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Charlotte
- Charles UpchurchCharlotte$343K
- Elizabeth HarrisCharlotte$120K
- Adam SpitzCharlotte$33K
- Raymond StadiemCharlotte$32K
- Nisha NathanCharlotte$31K
- David BrantleyCharlotte$27K
- Kanakasabai NarasimhanCharlotte$25K
- Gary RolbandCharlotte$18K
- Kathryn LucasMorehead City$37.9M
- Mark WarrenGreenville$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.